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Available online 21 August 2016The region known as pX in the 3′ end of the human T-cell lymphotropic virus type 1 (HTLV-1) genome contains
four overlapping open reading frames (ORF) that encode regulatory proteins. HTLV-1 ORF-I produces the protein
p12 and its cleavage product p8. The functions of these proteins have been linked to immune evasion and viral
infectivity and persistence. It is known that the HTLV-1 infection does not necessarily imply the development
of pathological processes and here we evaluated whether natural mutations in HTLV-1 ORF-I can inﬂuence the
proviral load and clinical manifestation of HTLV-I-associated myelopathy/tropical spastic paraparesis (HAM/
TSP). For that, we performed molecular characterization, datamining and phylogenetic analysis with HTLV-1
ORF-I sequences from 156 patients with negative or positive diagnosis for HAM/TSP. Our analyses demonstrated
that some mutations may be associated with the outcome of HAM/TSP (C39R, L40F, P45L, S69G and R88K) or
with proviral load (P34L and F61L). We further examined the presence of mutations in motifs of HBZ and ob-
served that P45L mutation is located within the HBZ nuclear localization signal and was found more frequently
between patients with HAM/TSP and high proviral load. These results indicate that some natural mutations are
located in functional domains of ORF-I and suggests a potential association between thesemutations and the pro-
viral loads and development of HAM/TSP. Therefore it is necessary to conduct functional studies aimed at evalu-
ating the impact of these mutations on the virus persistence and immune evasion.
© 2016 Elsevier B.V. All rights reserved.Keywords:
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HAM/TSP1. Introduction
The human T-cell lymphotropic virus type 1 (HTLV-1) was the ﬁrst
human retrovirus identiﬁed that is associated with disease, including
adult T cell leukemia/lymphoma (ATLL), tropical spastic paraparesis/
HTLV-associated myelopathy (HAM/TSP), and infective dermatitis,
polymyositis (Gessain et al., 1985; Goncalves et al., 2003; Poiesz et al.,
1980; Yoshida et al., 1982). A recent research based on individuals
originated from known HTLV-1 endemic areas estimates 5–10 million
infected individuals (Gessain and Cassar, 2012). Indeed, HTLV-1 infec-
tion does not necessarily imply the development of pathological).processes and themajority of infected individuals remain asymptomat-
ic, with only a low percentage of individuals developing HAM/TSP (0.3–
2%) (Kaplan et al., 1990;Maloney et al., 1998). Studies indicate that high
proviral load is typically seen in individuals with a positive diagnosis of
HAM/TSP, when compared with infected individuals without the diag-
nosis for this disease (Nagai et al., 1998).
A region near the 3′ end known as pX encodes important regulatory
and accessory proteins shown to effect viral replication mechanisms
(Edwards et al., 2011; Lairmore et al., 2012, 2011). Transcription of this
region results in alternative forms of messenger RNA (mRNA), which
contains four partially overlapping open reading frames (ORFs) and an
antisense mRNA that generates the basic leucine zipper (HBZ) protein
(Berneman et al., 1992; Ciminale et al., 1992; Gaudray et al., 2002;
Koralnik et al., 1992). Interestingly the promoter of the four ORFs is 5′
LTR, but the HBZ promoter is in 3′ LTR (Berneman et al., 1992). Singly
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cleaved into thep8 protein. Differential splicing ofmRNA fromORF-II en-
codes the proteins, p30 andp13. TheORF-III andORF-IV produce the pro-
teins Rex and Tax, respectively (Ciminale et al., 1992; Johnson et al.,
2001; Kiyokawa et al., 1985, 1984; Koralnik et al., 1992).
The expression of ORF-I in infected cells has been shown to regulate
the biologically activity of HTLV-1, inﬂuencing the virus infectivity and
persistence (Pise-Masison et al., 2014). The p12 protein resides in the
endoplasmic reticulum and its expression increases the intracellular
calcium concentration from the ER through inositol trisphosphate re-
ceptors, consequently promoting the dephosphorylation of activate nu-
clear factor of activated T-cells (NFAT) (Albrecht et al., 2002; Ding et al.,
2002; Fukumoto et al., 2009). In addition, p12 can bind newly synthe-
sized major histocompatibility complex class I (MHC I) molecules, re-
ducing its expression on the cell surface. Although downregulation of
MHC class I triggers NK cell activation, HTLV-1 infected cells are resis-
tant to NK cell killing through p12's reduction of cell surface ICAM-1
and ICAM-2 (Banerjee et al., 2007).
The p12 protein undergoes double proteolytic cleavage. The ﬁrst
cleavage occurs between amino acid positions 9 and 10 and removes
the ER retention/retrieval signal of p12. The second cleavage occurs be-
tween amino acids 29 and 30 and generates the p8 protein (Edwards et
al., 2011). The p8 protein resides at the cell surface and its expression in-
duces cellular conduits and enhances virus transmission (Van Prooyen
et al., 2010).
Trovato et al. demonstrated two natural allelic variants of p12: a ly-
sine-to-arginine change at position 88, which was found more fre-
quently in patients with HAM/TSP and could be important for HTLV-1
outcome (Trovato et al., 1999). More recent studies on ORF-I suggest
the co-dependence of p12 and p8 proteins to virus persistence and
demonstrated that natural mutationswithin ORF-I sequences can affect
the relative amounts of these proteins (Pise-Masison et al., 2014). Here,
we demonstrate that natural mutations in HTLV-1 ORF-I might inﬂu-
ence the proviral load and clinical manifestation of HAM/TSP.
2. Materials and methods
To perform the molecular analysis of ORF-I HTLV-1 we analysed
1530 HTLV-1 ORF-I sequences of different isolated cell clones from a
total of 156 HTLV-1-infected subjects. These samples were obtained
from the Centre Hospitalier Universitaire de Fort-de-France in Marti-
nique, the Institut Pasteur de Cayenne in French Guyana, the Bahia
School of Medicine and Public Health and the National Institutes of
Health Clinical Center. Blood samples from these individuals were ob-
tained and the DNA extracted from PBMCs was used to determine the
proviral load using Real-time PCR of Tax. The same DNA was used for
ampliﬁcation of ORF-I through PCR reactions and these PCR products
was puriﬁed and cloned into speciﬁc vector. Five to twenty clones per
patient were isolated and sequenced. These methods were described
in detail by Pise-Masison et al.(Pise-Masison et al., 2014).
The ﬁnal dataset was composed of 879 HTLV-1 ORF-I sequences
from 86 patients with not HAM/TSP, referred to as Health Carrier
(HC), and 651 HTLV-1 ORF-I sequences from 70 patients with HAM/
TSP. These sequenceswere originated fromdifferent geographic regions
(Caribbean, France, North America, Africa, and Brazil) and classiﬁed ac-
cording to a negative or positive diagnostic for HAM/TSP. All samples
were anonymized and the clinical classiﬁcationwas carried out bymed-
ical experts according to World Health Organization (WHO). The re-
search was conformed to the guidelines of the ethics review board of
theNational Cancer Institute and informed consentwaswritten and ob-
tained from each subject.
2.1. Molecular characterization
The genetic distances among the sequences from patient with nega-
tive or positive diagnosis for HAM/TSP were measured within andbetween the different datasets using the MEGA 5.05 program and the
analyses about the proviral load was conducted using the STATA pro-
gram. The statistical analyses of the proviral load were performed
usingMann-Whitney test and a P value lower than 0.05was considered
statistically signiﬁcant.
Since we get differing numbers of clones from each patient, the
characterization of mutations was determined by a qualitative anal-
ysis considering the presence or absence of variants among the se-
quences of each individual. If one of the patient sequences has the
variant we consider that the patient has the mutation (Geneious
5.6.5 program). We selected the most frequent natural mutations
within ORF-I sequences (F3L, S23P, D26N, G29S, P34L, C39R, L40F,
P45L, F61L, S63P, L66P, S69G, R83C, R88K and P91S) to evaluate
their possible association with the development of HAM/TSP using
the Excel program. The statistical analyses were performed using
Fisher's exact test and a P value lower than 0.05 was considered sta-
tistically signiﬁcant.
2.2. Datamining
Weused a two-step approach, using an unsupervisedmethod for at-
tribute selection (naïve Bayesian networks analysis), followed by a su-
pervised method for disease progression classiﬁcation (Decision tree
J48). A Bayesian network (BN) is a probabilistic model that describes
statistical conditional dependencies between multiple variables. In this
study, we learn Bayesian networks from observation of the attributes.
Dependencies are visualized in a directed acyclic graph and form the
qualitative component of the BN. In this graph, each node corresponds
to an attribute, and a direct arc between nodes represents a direct inﬂu-
ence. Mathematically, a Bayesian network provides a refactoring of the
Joint Probability Distribution (JPD) of the data, using Bayes' rules. As a
BN simpliﬁes the JPD, it provides an effective model that summarizes
statistical properties of the data. In this way, the best Bayesian network
is searched that explains amaximumof the observed associations in the
data using a minimum number of direct inﬂuences. Bayesian network
learning was performed using the B-course software adapted by
Deforche et al. (Deforche et al., 2006). In this non-linearmodel, the con-
ditional dependency was assessed with a nonparametric bootstrap
(100× replicates) (Friedman et al., 2013). The Decision tree J48 strategy
is based on divide-and-conquer approach, sometimes called top-down
induction of decision trees. It was developed and reﬁned by J. Ross
Quinlan at the University of Sydney in Australia. Divide-and-conquer al-
gorithms operate by adding tests to the tree that is under construction,
always striving tomaximize the separation between the classes. Each of
these involves ﬁnding an attribute to split on. The state of the art for
error evaluation, independently from the loss functions, is to execute
the 10-fold cross validation when a test set is unavailable. To execute
and validate J48 decision tree approach we used the data mining suite
Weka (E. WiaF, 2011).
2.3. Phylogenetic analysis
The phylogenetic analysis was performed using consensus se-
quences of patients from Brazil. Clustal-X was used for the alignment
and the TN93 model of nucleotide substitution was selected using
jModelTest. The maximum likelihood tree was inferred using PhyML
online tool and bootstrap analysis (1000 replicates) was used to calcu-
late the statistical support of the tree branches. Tree visualization and
editing was done using FigTree v.1.2.2.
3. Results
3.1. Descriptive characteristics of the study samples
In this study, we analysed HTLV-1 ORF-I sequences from a total of
156 HTLV-1-infected subjects. Our ﬁnal dataset was composed of 879
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HAM/TSP individuals (HC) and 651 HTLV-1 ORF-I sequences from inde-
pendently isolated clones of 70 patients diagnosedwithHAM/TSP (Pise-
Masison et al., 2014). The median proviral load of patients with HAM/
TSP was 22.9 copies/100 cells (IQR 11.9–47.6) which was signiﬁcantly
higher than HC, whose median proviral load was 8.7 copies/100 cells
(IQR 0,5–17,8) (p b 0,0001).
Next, we measured the genetic distance between sequences using
the MEGA 5.05 program. Interestingly, we found that the diversity be-
tween sequences from patients with HAM/TSP (0.014) was lower than
that found between sequences from heath carrier (0.017).Fig. 1. Frequency of naturalmutationswithin ORF-I sequences. The characterization of mutation
among the clone sequences of each individual. (A) The graph represents a comparison betw
Comparison between patients with high and low proviral loads (PVL). High PVL are indicate
frequency was graphed for HAM/TSP patients with high PVL (black bar), HAM/TSP with low
(striped bar). The phenotype of ORF-I protein expression is: Mostly expression of p12 (F3L,
Same expression of p12 and p8 (S69G, R83C, R88K, S91P). P values were calculated by the Fish3.2. Association of mutations in ORF-I sequences from HTLV-1-infected pa-
tients with proviral load and clinical deﬁnition
We analysed the presence or absence of ﬁfteen amino acid changes
(F3L, S23P, D26N, G29S, P34L, C39R, L40F, P45L, F61L, S63P, L66P,
S69G, R83C, R88K and P91S) that inﬂuence the expression proﬁle of
the HTLV-1 ORF-I protein product. As previously described (Pise-
Masison et al., 2014), these mutations resulted in three patterns of
ORF-I protein expression: higher levels of p8 expression, higher levels
of p12 expression or an equivalent level of p8 and p12 expression. We
then compared the frequency of each mutation in non-HAM/TSPswas determined by a qualitative analysis considering the presence or absence of variants
een patients with positive or negative diagnosis of HAM/TSP for a given mutation. (B)
d by white bars and the patients with low PVL are indicated by black bars. (C) Mutation
PVL (dotted bar), no HAM/TSP (HC) with high PVL (white bar) and HC with low PVL
S23P, G29S, P34L, C39R,L40F, P45L, F61L, S63P, L66P); Mostly expression of p8 (D26N);
er's exact test.
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amino acid sequence and proviral load was performed (Fig. 1).
As shown in Fig. 1A, mutations P45L, S69G and R88K were found
more frequently in patients with a positive diagnosis for HAM/TSP,
whereas mutations C39R and L40F were found more frequently in HC.
Of note, Trovato et al. showed that a lysine residue at position 88
destabilized the p12 protein by proteasomal degradation and that this
mutation could be associated with HAM/TSP (Trovato et al., 1999).
While this mutation was found more frequently in HAM/TSP patients
than HC, we did not ﬁnd a correlation between R88K and proviral load
(Fig. 1B).
In contrast, mutations D26N, P34L, C39R, F61L and R83C were asso-
ciated with low proviral load and P45L with high proviral load (Fig. 1B).
A combined classiﬁcation of proviral load and clinical diagnosis reveals
mutations D26N and F61L are associated with low proviral load and
HC, whereasmutations S63P and R83C are associatedwith high proviral
load and HAM/TSP (Fig. 1C). The mutations P34L and S91P appear most
frequently (Nthan 40% of the sequences analysed) but are not associated
with the development of HAM/TSP. However, as seen in Fig. 1B, there
was a higher frequency of P34L sequences in individuals with low pro-
viral load.
Similarly, mutations C39R and F61L were more frequently found
in patients with low proviral load (Fig. 1B). These three mutations
(P34L, C39R and F61L) that result in predominant expression of
p12 are associated with low proviral load. Whereas, the mutation
D26N, the only mutation that resulted in predominant p8 expres-
sion, was not associated with the development of HAM/TSP but
was associated with low proviral load and HC (Fig. 1B and C). These
results are consistent with that of Pise-Masison et al. (Pise-Masison
et al., 2014), where predominant expression of either p12 or p8
was associated with low proviral load.
Low proviral load in some individuals might also be inﬂuenced by
alterations in remaining open reading frames in which other acces-
sory proteins are encoded, such as viral protein HTLV-1 bZIP factor
(HBZ). As described in previous studies, HBZ is encoded by the com-
plementary strand of the HTLV-1 genome (7292 to 6666) and seems
to play a role in cellular transformation, survival and proliferation
(GenBank: U19949) (Matsuoka, 2010; Matsuoka and Green, 2009).
Here, we further examined the presence of these mutations in motifs
of HBZ and only four mutations in ORF-I resulted in changes in the
HBZ ORF: P34L, P45L, L66P and R88K. Among them, only the P45L
mutation is located within the motif previously described (HBZFig. 2. Analysis of interactions amongmutations in ORF-I, proviral load, and development of HA
HC fromBrazil. This dataset is composed of 27HAM/TSP patients [median of 9 samples/patient, I
p=0.43). (B) Discovery of hidden conditional dependencies betweenproviral load andORF-1m
measurementswere discretized in 25% quartile and the resultswere represented as binary decis
the accuracy deﬁned per decision branch (%). This dataset is composed of 938 samples (Ov
measure = 0.65 and AUC = 0.8).nuclear localization signal) and was found more frequently between
patients with HAM/TSP and high proviral load.3.3. Datamining approach reveals that mutation interactions are necessary
to deﬁne HAM/TSP pathogenesis
To reveal possible interactions among speciﬁc mutations in ORF-I,
proviral load, and disease deﬁnition, we employed a two-step ap-
proach, using an unsupervised method for attribute selection
(naive Bayesian networks analysis, BN), followed by a supervised
method for disease progression classiﬁcation (Decision tree J48).
First, Bayesian network analysis with all sequences showed a central
association among disease progression, proviral load and patient or-
igin, that interacted directly with mutations in ORF-I region: D26N,
G29S, P34L, L40F, P45L, S63P, L66P, S69G, R83C. This ﬁrst BN analysis
revealed a possible biased geographical distribution of mutation
prevalence given that in our dataset we do not have sequences
from patients HC and HAM/TSP from all the geographic regions
(data not shown). Due to this, we decided to use only samples from
Brazil (27 HAM/TSP patients [median of 9 samples/patient, IQR =
7–17] and 48 HC [median of 10.5 samples/patient, IQR = 8–19]).
No statistical signiﬁcance was observed between the medians of
the number of samples per HAM/TSP patients and HC (Fig. 2A). We
then applied Decision tree J48 to predict HAM/TSP samples,
conﬁrming univariate analysis and revealing hidden conditional de-
pendencies among mutations and proviral load (Fig. 2B). We ob-
served several interactions associated with a true positive rate of
0.63 for HAM/TSP, as among D26N mutation and high proviral load
or interactions between high proviral load, 26D, 29G and 34P. The
predicted results above were plotted in a matrix 2 × 2 and Sensitiv-
ity, Speciﬁcity, Positive Predictive Values and Negative Predictive
Values were described in Table 1.
Since sequences “states” are not statistically independent observa-
tions and these ﬁndings between mutations and disease manifestation
could be associatedwith shared ancestry inherent,we performed a phy-
logenetic analysis using sequences of patients from Brazil (n = 75 con-
sensus sequences) but the phylogenetic tree presented poor
phylogenetic signal with no bootstrap support. This result might be ex-
plained due to theHTLV-1ORF-I being a short region (300 bp) and high-
ly conserved and it is known that the indicated region for subtyping
HTLV-1 is LTR (Alcantara et al., 2009).M/TSP. (A) Comparison of number of samples sequenced between HAM/TSP patients and
QR=7–17] and 48HC [median of 10.5 samples/patient, IQR=8–19] (MannWhitney test,
utations associatedwith HAM/TSP. To reduce noise in the statistical analysis, proviral load
ion tree graphs. Nodes outline the chosen attributes and thenumber (n=) of instances and
erall Accuracy = 78.25%, Detailed accuracy per HAM/TSP: True positive rate = 0.60, f-
Table 1
Results of conditional dependencies between proviral load, ORF-1mutations and clinical status. TheORF-I sequenceswere originated from different isolated cell clones of HTLV-1-infected
patients from Brazil. PPV means positive predictive value and NPV means negative predictive value.
Conditional dependency:
Proviral load (PVL) and mutation (AA) Prediction
Sequences Parameter (%)
HC
(n = 616)
HAM/TSP
(n = 322) Sensitivity Speciﬁcity PPV NPV
Low PVL HC 283 24 86 63 82 70
High PVL + 26N HAM/TSP 0 17
High PVL + 26D + 29S HC 83 31
High PVL + 26D + 29G + 34P HAM/TSP 79 166
High PVL + 26D + 29G + 34L + 83C HAM/TSP 8 21
High PVL + 26D + 29G + 34L + 83R HC 163 63
424 F.K. Barreto et al. / Infection, Genetics and Evolution 45 (2016) 420–4254. Discussion
HTLV-1 infection does not necessarily imply the development of
pathological processes and it is not known what determines the mani-
festation of the disease in an infected individual. To date, proviral DNA
levels in the blood are the best predictor of risk for the development
of HAM/TSP (Matsuzaki et al., 2001; Yamano et al., 2002). Here, we de-
scribedHTLV-1ORF-Imutations that are associatedwith disease pheno-
type and may inﬂuence the outcome of infection and the development
of HAM/TSP.
Computational analysis of the amino acid sequence of p12 predicts
the existence of several functional domains, including a noncanonical
endoplasmic reticulum (ER) retention signal, two leucine zipper (LZ)
motifs, two transmembrane domains, a calcineurin-binding motif and
four proline-rich Src homology 3 (SH3)-binding domains (Ding et al.,
2002; Fukumoto et al., 2009). Somemutations analysed here are located
in functional domains of ORF-I and may be associated with clonal ex-
pansion of HTLV-1-infected cells. The D26N and F61L mutations are lo-
cated in the ﬁrst and second transmembrane domains, respectively, and
are found more frequently in patients with low proviral load, as shown
in Fig. 1B. Our data support studies that suggest co-expression of p12
and p8 are important for efﬁcient viral persistence (Pise-Masison et
al., 2014).
Only R83C mutation is located in a calcineurin-binding motif and is
associated with low proviral load. Calcineurin plays a crucial role in T-
cell activation, in part, by dephosphorylating the nuclear factors of acti-
vated T cells (NFATs). NFAT is essential for activating cytokine gene ex-
pression and, thus, the immune response (Kim et al., 2003). p12 is able
tomediate an increase in cytosolic calcium in T-cells by increasing calci-
um release from the ER (Kim et al., 2003). By depleting ER calcium
stores and increasing cytosolic calcium, p12 can modulate cellular pro-
cesses including T-cell proliferation, viral replication, and viral spread.
Early studies on ORF-I showed that it activates NFAT (Albrecht and
Lairmore, 2002; Kim et al., 2003). Therefore, mutations in the calcine-
urin binding region of ORF-I could affect NFAT activity and impact the
immune response and viral replication.
Lowproviral loadmight also be inﬂuenced by alterations in other ac-
cessory proteins, such as HBZ protein, that seems to play a role in cellu-
lar transformation, survival and proliferation (Albrecht and Lairmore,
2002; Gaudray et al., 2002; Matsuoka and Green, 2009). Here, we dem-
onstrated only the P45L mutation is located within the HBZ nuclear lo-
calization signal and was foundmore frequently between patients with
HAM/TSP and high proviral load. This ﬁnding is consistent with results
showing that HBZ down-regulates Tax-induced HTLV-1 transcription
and thus viral replication (Matsuoka, 2010;Matsuoka andGreen, 2009).
Many different machine-learning tools have been used to predict
therapy failure and conditional dependency among drug resistancemu-
tations (Pineda-Pena et al., 2014; Prosperi and De Luca, 2012). Here, our
data mining approach conﬁrmed the association among HAM/TSP, pro-
viral load and speciﬁc single mutations found with univariate analysis.
Moreover, it revealed unexpected conditional dependencies among
proviral load andmutations in ORF-1 associatedwith HAM/TSP. Despite
the high prevalence of P34L mutation and its association with proviralload, this mutation alone could not determine disease. Only the data
mining approach revealed the coordinate dependency between proviral
load, P34L and P45L to be associated with HAM/TSP.
5. Conclusions
The results presented in this study suggest that some ORF-I natural
mutations may be associated to HAM/TSP development and to the pro-
viral load of HTLV-1-infected individuals. Is important to note that
HTLV-1 have four open reading frames (ORFs) in the pX region and all
regulatory proteins play a key role in viral pathogenesis. Therefore to in-
vestigate better the contribution of mutations found in HTLV-1 ORF-I to
the development of HAM/TSP, it is necessary to conduct functional stud-
ies aimed at evaluating the impact of these mutations on the virus per-
sistence and immune evasion.
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